Last Year‎ > ‎

Cole Maxwell & Isabella Jennings

Project Summary
This study reports the design of a potential drug candidate for the effective treatment of neurological disorders associated with human immunodeficiency virus (HIV) infections of the brain. HIV infections of the brain, which current drugs are unable to efficiently treat, lead to severe neurological disorders, seizures, and in severe cases, coma. Our design aims to simultaneously target two highly expressed G-protein coupled receptors found in the brain and in the immune cells, namely the cannabinoid receptor 2 (CB2), a target associated with antinociception and inflammation, and the C-C chemokine receptor 5 (CCR5), a drug target that prevents HIV from infecting host cells. The drug candidate includes a bivalent ligand with an optimal spacer length, which other studies have suggested provide synergistic effects. By optimally tethering maraviroc, an HIV/AIDS drug, to a CB2 selective agonist, we expect the designed ligand will effectively cross the blood-brain-barrier, suppress pain, lower inflammation, and reduce HIV proliferation.
 Cole Maxwell

Bio information about team member 1 
Bio information about team member 1  Bio information about team member 1  Bio information about team member 1  Bio information about team member 1  Bio information about team member 1  Bio information about team member 1  Bio information about team member 1  Bio information about team member 1  Bio information about team member 1  Bio information about team member 1  Bio information about team member 1  Bio information about team member 1  Bio information about team member 1  Bio information about team member 1  Bio information about team member 1  Bio information about team member 1  Bio information about team member 1   Bio information about team member 1  Bio information about team member 1  Bio information about team member 1  Bio information about team member 1  Bio information about team member 1  Bio information about team member 1  Bio information about team member 1  Bio information about team member 1  Bio information about team member 1  Bio information about team member 1  Bio information about team member 1 
   Isabella Jennings

Bio information about team member 2  Bio information about team member 2 Bio information about team member 2 Bio information about team member 2 Bio information about team member 2 Bio information about team member 2 Bio information about team member 2 Bio information about team member 2 Bio information about team member 2 Bio information about team member 2 Bio information about team member 2 Bio information about team member 2 Bio information about team member 2 Bio information about team member 2 Bio information about team member 2 Bio information about team member 2 Bio information about team member 2 Bio information about team member 2 Bio information about team member 2 Bio information about team member 2 Bio information about team member 2 Bio information about team member 2 Bio information about team member 2 Bio information about team member 2 Bio information about team member 2 Bio information about team member 2 Bio information about team member 2 Bio information about team member 2 Bio information about team member 2

Honors & Awards
Cole Maxwell (2018) & Isabella Jennings (2017) worked at the Center for Drug Design at the University of Minnesota under the guidance of Dr. Yuk Sham. Isabella and Cole were regional finalists in the Siemens Competition. At the regional science fair, they qualified to compete in the Tri-State Junior Science and Humanities Symposium and observe the State Science and Engineering Fair. At JSHS, Bella and Cole were named the 6th place project overall and alternates to advance to the National JSHS competition. They were also recognized by the Minnesota Scholars of Distinction Award Program for their Meritorious Performance in Science, and their paper was also chosen as one of the top 10 MAS STEM Communicator Award Winners.